Lectin Mediated Biorecognition as a Novel Strategy for Targeted Delivery to Bladder Cancer

被引:32
作者
Neutsch, Lukas [1 ]
Plattner, Verena E. [1 ]
Polster-Wildhofen, Sonja [2 ]
Zidar, Agnes [1 ]
Chott, Andreas [3 ]
Borchard, Gerrit [4 ]
Zechner, Othmar [2 ]
Gabor, Franz
Wirth, Michael [1 ]
机构
[1] Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, A-1090 Vienna, Austria
[2] Wilhelminenspital Stadt Wien, Dept Urol, Vienna, Austria
[3] Wilhelminenspital Stadt Wien, Dept Pathol & Microbiol, Vienna, Austria
[4] Univ Geneva, Lab Pharmaceut & Biopharmaceut, CH-1211 Geneva 4, Switzerland
关键词
urinary bladder; carcinoma; drug delivery systems; lectins; administration; intravesical; MITOMYCIN-C; EFFICACY; BINDING; DIFFERENTIATION; NANOPARTICLES; ENDOCYTOSIS; THERAPY; CELLS;
D O I
10.1016/j.juro.2011.05.040
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Inadequate urothelial delivery of drugs is considered a primary cause of current shortcomings in adjuvant intravesical chemotherapy for bladder cancer. We report what is to our knowledge a novel biorecognitive approach to achieve more regionally selective targeting of malignant tissue and improve urothelial uptake based on specific interaction between lectins and bladder cell glycocalyces. Materials and Methods: We assessed the cytoadhesive and cytoinvasive potential of selected plant lectins in 3 human urothelial cell lines, corresponding to healthy tissue, and low and high grade carcinoma, respectively. Flow cytometry and fluorimetry were used to determine binding capacity and specificity in single cells and confluent monolayers. Monensin quenching experiments, microscopic analysis and enzyme treatment allowed further characterization of internalization, the uptake pathway and the potential cause of tumor selectivity. Results: Wheat germ agglutinin had the highest bioadhesive potential while peanut agglutinin was the most potent discriminator between healthy and cancerous tissue (p < 0.01). In each case cell interaction was highly specific (greater than 80%) and proved decisive for efficient uptake. Within 60 minutes after exposure greater than 50% of membrane bound lectins were internalized in acidic compartments. Cancer associated aberrant glycosylation likely represents the determining cause of peanut agglutinin selectivity. Conclusions: Given careful choice of the targeting ligand, the development of carbohydrate based delivery strategies for bladder cancer therapy seems feasible. Lectin bioadhesion may not only mediate preferential accumulation in malignant tissue but also promote cellular internalization via increased recruitment of membrane bound material to physiological uptake routes.
引用
收藏
页码:1481 / 1488
页数:8
相关论文
共 28 条
[1]   Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial [J].
Au, JLS ;
Badalament, RA ;
Wientjes, MG ;
Young, DC ;
Warner, JA ;
Venema, PL ;
Pollifrone, DL ;
Harbrecht, JD ;
Chin, JL ;
Lerner, SP ;
Miles, BJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (08) :597-604
[2]   Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors [J].
Bilensoy, Erem ;
Sarisozen, Can ;
Esendagli, Guenes ;
Dogan, A. Lale ;
Aktas, Yesim ;
Sen, Murat ;
Mungan, N. Aydin .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 371 (1-2) :170-176
[3]   Improving efficacy of intravesical chemotherapy [J].
Burgues Gasion, Juan Pablo ;
Jimenez Cruz, Juan Fernando .
EUROPEAN UROLOGY, 2006, 50 (02) :225-234
[4]   Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli [J].
Dhakal, B. K. ;
Kulesus, R. R. ;
Mulvey, M. A. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 :2-11
[5]   Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study [J].
Di Stasi, SM ;
Giannantoni, A ;
Stephen, RL ;
Capelli, G ;
Navarra, P ;
Massoud, R ;
Vespasiani, G .
JOURNAL OF UROLOGY, 2003, 170 (03) :777-782
[6]   Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? [J].
Dobruch, Jakub ;
Herr, Harry .
BJU INTERNATIONAL, 2009, 104 (02) :170-174
[7]   Drug delivery systems in urology - Getting "smarter" [J].
Farokhzad, Omid C. ;
Dimitrakov, Jordan D. ;
Karp, Jeffrey M. ;
Khademhosseini, Ali ;
Freeman, Michael R. ;
Langer, Robert .
UROLOGY, 2006, 68 (03) :463-469
[8]   The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery [J].
Gabor, F ;
Bogner, E ;
Weissenboeck, A ;
Wirth, M .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (04) :459-480
[9]   Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update [J].
Hall, M. Craig ;
Chang, Sam S. ;
Dalbagni, Guido ;
Pruthi, Raj Som ;
Seigne, John Derek ;
Skinner, Eila Curlee ;
Wolf, J. Stuart, Jr. ;
Schellhammer, Paul F. .
JOURNAL OF UROLOGY, 2007, 178 (06) :2314-2330
[10]   Bladder Cancer: Narrowing the Gap Between Evidence and Practice [J].
Hussain, Maha H. A. ;
Wood, David P. ;
Bajorin, Dean F. ;
Bochner, Bernard H. ;
Dreicer, Robert ;
Lamm, Donald L. ;
O'Donnell, Michael A. ;
Siefker-Radtke, Arlene O. ;
Theodorescu, Dan ;
Dinney, Colin P. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5680-5684